Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma

Tytuł :
Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma
Autorzy :
Lin G
Wang B
Wu X
Sun T
Chen L
Lu C
Wang N
Pokaż więcej
Temat :
intrahepatic cholangiocarcinoma
apatinib
efficacy
toxicity
progression-free survival
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło :
Cancer Management and Research, Vol Volume 12, Pp 11523-11526 (2020)
Wydawca :
Dove Medical Press, 2020.
Rok publikacji :
2020
Kolekcja :
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Typ dokumentu :
article
Opis pliku :
electronic resource
Język :
English
ISSN :
1179-1322
Relacje :
https://www.dovepress.com/efficacy-and-safety-of-apatinib-treatment-for-patients-with-advanced-i-peer-reviewed-article-CMAR; https://doaj.org/toc/1179-1322
Dostęp URL :
https://doaj.org/article/8d7c40b8fa8a4bdeb69b24f86bb877fd
Numer akcesji :
edsdoj.8d7c40b8fa8a4bdeb69b24f86bb877fd
Czasopismo naukowe
Guohe Lin,1,* Bicheng Wang,2,* Xiuwei Wu,1 Tong Sun,1 Lili Chen,1 Canliang Lu,3 Nianfei Wang1 1Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, People’s Republic of China; 2Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, People’s Republic of China; 3Department of Hepatopancreatobiliary Surgery, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, People’s Republic of China*These authors contributed equally to this workCorrespondence: Nianfei WangDepartment of Oncology, The Second Affiliated Hospital of Anhui Medical University, Furong Road No. 678, Hefei, Anhui 230601, People’s Republic of ChinaEmail wangnianfei@foxmail.comCanliang LuDepartment of Hepatopancreatobiliary Surgery, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Jixi Avenue No. 218, Hefei, Anhui 230022, People’s Republic of ChinaEmail lucanliang@163.comPurpose: Effective treatment options for intrahepatic cholangiocarcinoma (ICC) are limited. This study was intended to explore the efficacy and safety of apatinib in advanced ICC with lymph node metastasis or distant metastasis.Patients and Methods: The efficacy and toxicity of apatinib were evaluated in patients with ICC between November 2017 and March 2020 at the Second Affiliated Hospital of Anhui Medical University. Survival analysis was estimated using Kaplan–Meier method.Results: Ten patients with advanced ICC were enrolled. The median progression-free survival (PFS) was 3.0 months (95% CI: 1.450– 4.550). No patient achieved a complete response (CR). One patient gained partial response (PR), and 6 patients had stable disease (SD). The objective response rate (ORR) was 10%, and the disease control rate (DCR) was 70%. The common treatment-related adverse events were hypertension (20%), proteinuria (30%), hand and foot syndrome (10%) or emesis (10%). No grade 3/4 toxicities occurred. Toxicities were mild and tolerable.Conclusion: Apatinib is potentially an effective treatment option with tolerable toxicities for patients with advanced ICC.Keywords: intrahepatic cholangiocarcinoma, apatinib, efficacy, toxicity, progression-free survival

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies